C. Patrick

6.6k total citations · 2 hit papers
50 papers, 1.4k citations indexed

About

C. Patrick is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, C. Patrick has authored 50 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pulmonary and Respiratory Medicine, 32 papers in Oncology and 16 papers in Cancer Research. Recurrent topics in C. Patrick's work include Lung Cancer Treatments and Mutations (26 papers), Cancer Immunotherapy and Biomarkers (14 papers) and Cancer Genomics and Diagnostics (14 papers). C. Patrick is often cited by papers focused on Lung Cancer Treatments and Mutations (26 papers), Cancer Immunotherapy and Biomarkers (14 papers) and Cancer Genomics and Diagnostics (14 papers). C. Patrick collaborates with scholars based in United States, Austria and Australia. C. Patrick's co-authors include Zuan-Fu Lim, Daniel Morgensztern, Corey A. Carter, Bryan Oronsky, Stephen V. Liu, Alexander I. Spira, Ari M. Vanderwalde, Hossein Borghaei, Jorge J. Nieva and W. Michael Korn and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

C. Patrick

46 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas

2017 437 citations Bryan Oronsky, C. Patrick et al. Neoplasia profile →
Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy

2019 414 citations Zuan-Fu Lim, C. Patrick Journal of Hematology & Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Patrick United States	13	781	442	427	368	267	50	1.4k
Christopher C. Porter United States	24	497 0.6×	284 0.6×	984 2.3×	158 0.4×	109 0.4×	83	1.8k
Riccardo Marconcini Italy	17	1000 1.3×	166 0.4×	458 1.1×	189 0.5×	105 0.4×	48	1.3k
David Z. Chang United States	14	776 1.0×	500 1.1×	339 0.8×	116 0.3×	324 1.2×	19	1.3k
Stefania Beghelli Italy	19	1.4k 1.8×	1.0k 2.4×	503 1.2×	252 0.7×	529 2.0×	32	2.0k
Raymond Wadlow United States	14	485 0.6×	138 0.3×	484 1.1×	179 0.5×	62 0.2×	36	944
Tamotsu Sudo Japan	19	466 0.6×	346 0.8×	528 1.2×	255 0.7×	33 0.1×	57	1.5k
Ayman Rahman United States	15	567 0.7×	199 0.5×	469 1.1×	133 0.4×	67 0.3×	18	1.2k
Àlvaro Quintanal-Villalonga United States	16	623 0.8×	209 0.5×	676 1.6×	545 1.5×	29 0.1×	37	1.2k
Bo Gao Australia	19	781 1.0×	175 0.4×	984 2.3×	335 0.9×	34 0.1×	88	1.8k
Elena Roz Italy	15	849 1.1×	169 0.4×	808 1.9×	463 1.3×	39 0.1×	22	1.8k

Countries citing papers authored by C. Patrick

Since Specialization

Citations

This map shows the geographic impact of C. Patrick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Patrick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Patrick more than expected).

Fields of papers citing papers by C. Patrick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Patrick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Patrick. The network helps show where C. Patrick may publish in the future.

Co-authorship network of co-authors of C. Patrick

This figure shows the co-authorship network connecting the top 25 collaborators of C. Patrick. A scholar is included among the top collaborators of C. Patrick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Patrick. C. Patrick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sen, Utsav, Charles Coleman, Nishant Gandhi, et al.. (2025). SCD1 Inhibition Blocks the AKT–NRF2–SLC7A11 Pathway to Induce Lipid Metabolism Remodeling and Ferroptosis Priming in Lung Adenocarcinoma. Cancer Research. 85(13). 2485–2503. 11 indexed citations

Elliott, Andrew, Wendy Cozen, Evanthia T. Roussos Torres, et al.. (2024). Survival and mutational differences based on ESR1 and ESR2 expression in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8526–8526. 1 indexed citations

Elliott, Andrew, Stephen V. Liu, C. Patrick, et al.. (2024). A pan-tumor description of the genomic, transcriptomic, and immunological landscape of sodium-glucose cotransporter-2 (SGLT2) and association with clinical outcomes.. Journal of Clinical Oncology. 42(23_suppl). 104–104. 1 indexed citations

Espinoza, Magdalena, Andrew Elliott, Joanne Xiu, et al.. (2024). Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers. Nature Cancer. 5(7). 1121–1129. 11 indexed citations

Trabolsi, Asaad, Estelamari Rodríguez, Jennifer R. Ribeiro, et al.. (2024). Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors. The Oncologist. 29(11). e1480–e1491. 7 indexed citations

Luo, Jia, Narjust Florez, Yanyan Lou, et al.. (2024). Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRAS ^G12C -Mutated Non–Small Cell Lung Cancer: A Case Series and Literature Review. JCO Precision Oncology. 8(8). e2300644–e2300644. 3 indexed citations

Elliott, Andrew, Stephen V. Liu, C. Patrick, et al.. (2024). Abstract 5201: Characterization of PDLIM2 in non-small cell lung cancer. Cancer Research. 84(6_Supplement). 5201–5201. 1 indexed citations

Reuss, Joshua E., Nishant Gandhi, Phillip Walker, et al.. (2023). Spectrum of acquired KRAS mutations in driver mutation-positive non-small cell lung cancer.. Journal of Clinical Oncology. 41(16_suppl). 9069–9069.

Marks, Jennifer A., Nishant Gandhi, Balázs Halmos, et al.. (2023). Updated molecular analysis of MET exon 14skippingmutations (METex14) in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 41(16_suppl). 9095–9095. 2 indexed citations

10.

Kim, So Yeon, Jun‐Jie Yin, Phillip Walker, et al.. (2022). Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing. JTO Clinical and Research Reports. 3(9). 100381–100381. 13 indexed citations

11.

Mattes, Malcolm D., Timothy D. Eubank, Sijin Wen, et al.. (2021). A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non–Small Cell Lung Cancer. Clinical Lung Cancer. 22(4). 268–273. 21 indexed citations

12.

Albandar, Jasim M., et al.. (2021). Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?. Cancers. 13(5). 989–989. 44 indexed citations

13.

He, Yayi, Linsong Chen, Lishu Zhao, et al.. (2021). Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC. Theranostics. 11(14). 7092–7109. 11 indexed citations

14.

Patrick, C., et al.. (2020). Patterns of disease progression to checkpoint inhibitor immunotherapy in patients with stage IV non‐small cell lung cancer. Journal of Medical Imaging and Radiation Oncology. 64(6). 866–872. 4 indexed citations

15.

Hayes, Karen E., Samuel A. Sprowls, Erik A. Bey, et al.. (2020). Y Chromosome LncRNA Are Involved in Radiation Response of Male Non–Small Cell Lung Cancer Cells. Cancer Research. 80(19). 4046–4057. 35 indexed citations

16.

Jonna, Sushma, Rebecca Feldman, Jeffrey Swensen, et al.. (2019). Detection of NRG1 Gene Fusions in Solid Tumors. Clinical Cancer Research. 25(16). 4966–4972. 155 indexed citations

17.

Lim, Zuan-Fu & C. Patrick. (2019). Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. Journal of Hematology & Oncology. 12(1). 134–134. 414 indexed citations breakdown →

18.

Smolkin, Matthew B., et al.. (2019). Primary pleural epithelioid sarcoma of the proximal type: a diagnostic and therapeutic challenge. Translational Lung Cancer Research. 8(5). 700–705. 2 indexed citations

19.

Wu, Xiaoliang, Wenjuan Ma, Qianghua Zhou, et al.. (2017). AXL–GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases. Journal of Cancer Research and Clinical Oncology. 143(10). 1947–1957. 32 indexed citations

20.

Oronsky, Bryan, C. Patrick, Daniel Morgensztern, & Corey A. Carter. (2017). Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia. 19(12). 991–1002. 437 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact